Clinical Trial Update: A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus [Phase 2]

View source ↗

Summary

Phase II study evaluating axitinib in metastatic non-clear cell renal cell carcinoma previously treated with temsirolimus has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma Non-clear Cell

Drugs mentioned

• Axitinib (Axitinib)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Renal Cell Carcinoma, Nonclear Cell | Phase 2 | Status: COMPLETED